Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Inuvo Reports 26.4% Increase in Revenue to $75.6 Million for 2022

Published

on

<!– Name:DistributionId Value:8785538 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value:9537 –> <!– Name:CustomerId Value:1102598 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:7284a7d7-8fa6-419f-8927-a291c79c9b45 –>

Gross margin for the fourth quarter of 2022 increases to 68.0% from 57.1% last year

Inuvo management to host conference call at 4:15 PM ET on Thursday, March 9, 2023

LITTLE ROCK, Ark., March 09, 2023 (GLOBE NEWSWIRE) — Inuvo, Inc. (NYSE American: INUV), a leading provider of marketing technology, powered by artificial intelligence (AI) that serves brands and agencies, today provided a business update and announced its financial results for the fourth quarter and full year ended December 31, 2022.

Richard Howe, CEO of Inuvo, stated, “In 2022, we grew revenue, added new clients, and increased awareness. Throughout the year, we successfully implemented our strategy of bringing together Inuvo’s collective capabilities so we could better serve clients. As a result, I am pleased to report we achieved revenue growth of 26% for the fiscal year 2022.”

Mr. Howe continued, “As a technology company on the forefront of artificial intelligence, we continued to make significant AI advancements in 2022. There are many companies now asserting the integration of artificial intelligence into their solutions. There are few companies whose AI definition revolves around an intelligence that can discern the needs, emotions, and thinking of the humans it is designed to interact with, and this is exactly what differentiates the IntentKey from all other AI technologies within advertising.”

Financial Results for the Fourth Quarter and Full Year Ended December 31, 2022:

Net revenue for the fourth quarter of 2022 totaled $17.3 million, compared to $19.7 million for the same period last year. Although the fourth quarter of 2022 started strong, by December we experienced a softening in demand for advertising and lost a client. Net revenue for the full year ended December 31, 2022 totaled $75.6 million, an increase of approximately 26.4%, compared to $59.8 million for the same period last year.

Cost of revenue for the fourth quarter of 2022, totaled $5.5 million, compared to $8.5 million for the same period last year. The decrease in the cost of revenue for the three months ended December 31, 2022, as compared to the same period last year, was primarily related to the lower revenue in the current quarter. Cost of revenue for the full year ended December 31, 2022, totaled $30.2 million, as compared to $15.9 million for the same period last year. The increase in the cost of revenue for the full year ended December 31, 2022, as compared to 2021, was related to the growth associated with Direct revenue as a percentage of overall revenue.

Gross profit for the fourth quarter of 2022 and full year ended December 31, 2022 totaled $11.7 million and $45.4 million, respectively, as compared to $11.3 million and $43.9 million, respectively, for the same periods last year. Gross profit margin for the fourth quarter of 2022 and full year ended December 31, 2022 was approximately 68.0% and 60.0%, respectively, as compared to 57.1% and 73.4%, respectively, for the same periods last year.

Operating expenses for the fourth quarter of 2022 totaled $15.7 million, compared to $12.3 million for the same period last year. The higher operating expense is primarily due to increased traffic acquisition costs, corporate branding expense and accounts receivable reserve. Operating expenses for the full year ended December 31, 2022 totaled $58.0 million, compared to $51.7 million for the same period last year. Operating expenses for the full year ended December 31, 2022 included a marketing expense of $1.4 million related to client refunds for the invalid clicks purchased from a prominent advertising platform, from whom the Company expects reimbursement. The company has withheld payment of an equivalent amount of payables due to the advertising platform.

Other expense/income for the fourth quarter of 2022 and the full year ended December 31, 2022 was an expense of approximately $34 thousand and $436 thousand, respectively, compared to an expense of $158 thousand and an income of $257 thousand for the same periods last year. The other expense this year was due to unrealized and realized losses on trading securities. Other income, net, for the year ended December 31, 2021 included the reversal of deferred revenue from the contract cancellation of approximately $415 thousand and reversal of an accrued sales reserve of $50 thousand, partially offset by the unrealized losses on trading securities.

Net loss for the fourth quarter of 2022 was $4.0 million, or $0.03 per basic and diluted share, as compared to net loss of $1.2 million, or $0.01 per basic and diluted share, for the same period last year. Net loss for the full year ended December 31, 2022 totaled $13.1 million, or $0.11 per basic and diluted share, as compared to net loss of $7.6 million, or $0.06 per basic and diluted share, for the same period last year.

Adjusted EBITDA [see reconciliation table below] was a loss of approximately $1.8 million in the fourth quarter of 2022, compared to an Adjusted EBITDA income of approximately $307 thousand for the same period last year. Adjusted EBITDA was a loss of approximately $5.0 million for the full year ended December 31, 2022, compared to a loss of approximately $1.9 million for the same period last year.

Liquidity and Capital Resources:

On December 31, 2022, Inuvo had $4.5 million in cash, cash equivalents and short-term marketable securities, $2.8 million of working capital, an unused working capital facility of $5.0 million and no debt.

As of December 31, 2022, Inuvo had 120,137,124 common shares issued and outstanding.

Conference Call Details: 
Date: Thursday, March 9, 2023
Time: 4:15 p.m. Eastern Time 
Toll-free Dial-in Number: 1-877-407-9208
International Dial-in Number: 1-201-493-6784
Conference ID: 13736863
Webcast Link: HERE

A telephone replay will be available through Thursday, March 23, 2023. To access the replay, please dial 1-844-512-2921 (domestic) or 1-412-317-6671 (international). At the system prompt, please enter the code 13736863 followed by the # sign. You will then be prompted for your name, company, and phone number. Playback will then automatically begin.

About Inuvo

Inuvo®, Inc. (NYSE American: INUV) is a market leader in Artificial Intelligence built for advertising. Its IntentKey AI solution is a first-of-its-kind proprietary and patented technology capable of identifying and actioning to the reasons why consumers are interested in products, services, or brands, not who those consumers are. To learn more, visit www.inuvo.com.

Safe Harbor / Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including, without limitation risks detailed from time to time in our filings with the Securities and Exchange Commission (the “SEC”), and represent our views only as of the date they are made and should not be relied upon as representing our views as of any subsequent date. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” in Inuvo, Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed on March 9, 2023, and our other filings with the SEC.  Additionally, forward looking statements are subject to certain risks, trends, and uncertainties including the continued impact of Covid-19 on Inuvo’s business and operations. Inuvo cannot provide assurances that the assumptions upon which these forward-looking statements are based will prove to have been correct. Should one of these risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those expressed or implied in any forward-looking statements, and investors are cautioned not to place undue reliance on these forward-looking statements, which are current only as of this date. Inuvo does not intend to update or revise any forward-looking statements made herein or any other forward-looking statements as a result of new information, future events or otherwise. Inuvo further expressly disclaims any written or oral statements made by a fourth party regarding the subject matter of this press release. The information, which appears on our websites and our social media platforms is not part of this press release.

Inuvo Company Contact:
Wally Ruiz
Chief Financial Officer
Tel (501) 205-8397
[email protected]

Investor Relations:
David Waldman / Natalya Rudman
Crescendo Communications, LLC
Tel: (212) 671-1020
[email protected]

      (Tables follow)

               
INUVO, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
               
               
    Three Months Ended   Twelve Months Ended
    December 31   December 31   December 31 December 31
      2022       2021       2022     2021  
Net revenue   $ 17,270,886     $ 19,736,261 $ 75,603,745   $ 59,830,688  
Cost of revenue     5,527,244       8,459,820       30,244,387     15,925,837  
Gross profit     11,743,642       11,276,441       45,359,358     43,904,851  
Operating expenses              
Marketing costs     10,143,119       7,414,070       36,921,139     33,096,000  
Compensation     2,852,084       2,923,046       12,463,095     11,381,279  
General and administrative     2,680,971       1,971,476       8,624,998     7,198,213  
Total operating expenses     15,676,174       12,308,592       58,009,232     51,675,492  
Operating loss     (3,932,532 )     (1,032,151 )     (12,649,874 )   (7,770,641 )
Financing expense, net     (10,033 )     (50,342 )     (21,111 )   (86,983 )
Other income (expense) , net     (34,218 )     (158,493 )     (435,554 )   256,975  
Net loss     (3,976,783 )     (1,240,986 )     (13,106,539 )   (7,600,649 )
Other comprehensive income              
Unrealized gain (loss) on marketable securities     47,634       53,737       (138,605 )   53,737  
Comprehensive loss     (3,929,149 )     (1,187,249 )     (13,245,144 )   (7,546,912 )
               
Earnings per share, basic and diluted              
Net loss   ($ 0.03 )   ($ 0.01 )   ($ 0.11 ) ($ 0.06 )
Weighted average shares outstanding              
Basic     120,137,124       117,613,845       119,826,036     117,613,845  
Diluted     119,995,367       117,613,845       119,826,036     117,613,845  
INUVO, INC.  
CONDENSED CONSOLIDATED BALANCE SHEETS  
           
    (Unaudited)      
    December 31   December 31  
 
      2022       2021  
Assets          
           
Cash and cash equivalent   $ 2,931,415     $ 10,475,964  
Marketable securities-short term     1,529,464       1,927,979  
Accounts receivable, net     11,119,892       9,265,813  
Prepaid expenses and other current assets     798,977       1,408,186  
Total current assets     16,379,747       23,077,942  
           
Property and equipment, net     1,668,972       1,506,766  
           
Intangible assets, net of accumulated amortization   9,853,342       6,720,585  
Goodwill     5,649,291       9,853,342  
Other assets     2,005,957       2,838,439  
           
Total assets   $ 35,557,310     $ 43,997,074  
           
Liabilities and Stockholders’ Equity          
           
Current liabilities          
Accounts payable   $ 8,044,802     $ 4,844,716  
Accrued expenses and other current liabilities   5,550,984       5,817,823  
Total current liabilities     13,595,786       10,662,539  
           
Long-term liabilities     212,208       526,540  
           
Total stockholders’ equity     21,749,316       32,807,995  
Total liabilities and stockholders’ equity   $ 35,557,310     $ 43,997,074  
   
RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA
(unaudited)
             
    Three Months Ended   Twelve Months Ended
    December 31   December 31   December 31 December 31
      2022       2021       2022     2021  
Net loss   $ (3,976,783 )   $ (1,240,986 )   $ (13,106,539 ) $ (7,600,649 )
Financing expense, net     10,033       50,342       21,111     86,983  
Depreciation     402,989       332,918       1,527,663     1,277,664  
Amortization     276,738       551,700       1,175,222     2,188,251  
   EBITDA     (3,287,023 )     (306,026 )     (10,382,543 )   (4,047,751 )
Non-recurring or non-representaive items:          
Stock-based compensation     459,323       613,238       2,350,314     2,179,254  
Expense of fraudulent media                 1,367,800      
Realized and unrealized loss on investments     34,218             435,554      
Doubtful account reserve     975,243             1,237,774      
   Adjusted EBITDA     (1,818,239 )     307,212       (4,991,101 )   (1,868,497 )
               

Reconciliation of Operating Loss to EBITDA and Adjusted EBITDA 

We present EBITDA and Adjusted EBITDA as a supplemental measure of our performance. We defined EBITDA as Net loss plus (i) interest expense, (ii) depreciation, and (iii) amortization. We further define Adjusted EBITDA as EBITDA plus (iv) stock-based compensation and (v) certain identified expenses that are not expected to recur or be representative of future ongoing operation of the business. These adjustments are itemized above. You are encouraged to evaluate these adjustments and the reasons we consider them appropriate for supplemental analysis. In evaluating EBITDA and Adjusted EBITDA, you should be aware that in the future we may incur expenses that are the same or similar to some of the adjustments in the presentation. Our presentation of EBITDA and Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items.

 

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

THE 2024 GLOBAL EXPLORATION SUMMIT IS ANNOUNCED AT THE 120th EXPLORERS CLUB ANNUAL GALA IN NEW YORK

Published

on

the-2024-global-exploration-summit-is-announced-at-the-120th-explorers-club-annual-gala-in-new-york

Porto and Terceira Island to Host the ‘Davos of Exploration’ – The GLEX Summit
NEW YORK, April 24, 2024 /PRNewswire/ — The Explorers Club and Expanding World, are thrilled to announce the fifth edition of The GLEX Summit, known as the ‘Davos of Exploration,’ set to take place from June 15 to 19 on Porto city and Terceira Island in the Azores, Portugal.

This year, Porto will Ignite the summit, followed by two days of discussions and exploration in the historic city of Angra do Heroísmo on Terceira Island. From the depths of the oceans to new space missions, the power and future of exploration will be explored in these two World Heritage cities, deeply connected to the history of exploration.
The 2024 GLEX Summit will revolve around the latest discoveries and groundbreaking missions shaping the future of our planet. Highlights of the summit include the Artemis mission, which plans to send astronauts back to the moon for the first time since 1972, and the role of Space and the Oceans in researching and mitigating the effects of climate change. Notable sessions will also delve into the unfortunate incident of the submersible implosion that took place on Titan and the recording of an episode of the BBC’s acclaimed science comedy show ‘The Infinite Monkey Cage,’ hosted by physicist Brian Cox and comedian Robin Ince.
This prestigious event will bring together over three dozen explorer and scientist legends from around the world. Confirmed physicist and researcher Brian Cox, NASA Chief Scientist James Garvin, Aquanaut Fabien Cousteau, Oceanographer David Gallo, Cosmonaut Mike Massimino, Nasa ISS CapCom Tess Caswell, among many others global Explorers and Scientists.
For further inquiries about The GLEX Summit and press accreditation, please contact:
Marco Barbosa [email protected], +351917345744
Photo: https://mma.prnewswire.com/media/2395857/GLEX_Summit.jpg
 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/the-2024-global-exploration-summit-is-announced-at-the-120th-explorers-club-annual-gala-in-new-york-302125563.html

Continue Reading

Artificial Intelligence

Hillstone Networks is Named in Microsegmentation Solutions Landscape Report

Published

on

hillstone-networks-is-named-in-microsegmentation-solutions-landscape-report

Hillstone Networks delivers advanced Microsegmentation across different verticals.. 
SANTA CLARA, Calif., April 24, 2024 /PRNewswire/ — Hillstone Networks, a leading provider of cybersecurity solutions, has been included in the Forrester Microsegmentation Solutions Landscape, Q2 2024 report. The report offers an overview of the Microsegmentation market, focused on the vendors who deliver solutions for protection of critical resources, combating ransomware, and contributing to compliance adherence. The report provides security professionals a snapshot of these named vendors, considering factors such as size, geographic focus, and use cases to select the most suitable option for their targeted use cases or needs. 

In the Landscape Report, Forrester states that “Zero Trust is all about replacing bodies of implicit trust with explicit policy. In physical and virtual networks, the application of this principle is referred to as microsegmentation…. [It] was one of the first true Zero Trust technologies developed after Forrester published the initial Zero Trust reports.”  
Forrester states in the report that the main trend is “organizations are finally getting serious about Zero Trust. Some, proactively, are implementing microsegmentation as part of a Zero Trust strategy or initiative. Others are implementing it because they got hit by ransomware and are trying to avoid it again. But all of them are doing Zero Trust with microsegmentation.”
“Being recognized as a vendor in the Microsegmentation solution landscape underscores for us the pivotal role our technology plays in safeguarding critical assets and thwarting ransomware threats. We believe it reaffirms our commitment to providing cutting-edge security measures built on an innovative and AI-powered platform that help our customers defend against evolving cyber risks, ensuring resilience and trust,” states Tim Liu, CTO and Co-founder at Hillstone Networks.
Hillstone’s Microsegmentation solution provides the following key benefits:
Advanced and extensive Microsegmentation for physical servers, virtual machines, cloud hosts, and containers, seamlessly compatible with multiple platforms.Comprehensive, integrated Layer 4 to 7 security and malware features (Next Generation Firewall, Intrusion Prevention System, AntiVirus, URL filtering, DDoS, and bot defense), and complete vulnerability management across the entire application lifecycle.Distributed architecture for easy scaling and portability.Centralized and comprehensive visibility to reduce gaps in the threat surface.Learn more about Hillstone Networks solutions here.
About Hillstone Networks
Hillstone Networks’ Integrative Cybersecurity approach is based on a visionary, AI-powered, and accessible platform, delivering coverage, control, and consolidation to secure over 28,000 global enterprises.
Media ContactZeyao Hu+1 [email protected]
Logo – https://mma.prnewswire.com/media/765968/Hillstone_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/hillstone-networks-is-named-in-microsegmentation-solutions-landscape-report-302125530.html

Continue Reading

Artificial Intelligence

Tetra Pharm Technologies and Glysious Announce Collaboration to Develop Transdermal Combination Drugs Targeting the Endocannabinoid System

Published

on

tetra-pharm-technologies-and-glysious-announce-collaboration-to-develop-transdermal-combination-drugs-targeting-the-endocannabinoid-system

The collaboration brings together Tetra Pharm Technologies’ expertise in enabling technology with Glysious’ proprietary transdermal drug delivery system, renowned for its effectiveness, comfort, and convenience.
COPENHAGEN, Denmark, April 24, 2024 /PRNewswire/ — Tetra Pharm Technologies and Glysious are pleased to announce a strategic collaboration aimed at developing a ground-breaking transdermal drug delivery system complementing several of Tetra Pharm Technologies’ pipeline candidates. The joint invention aims to revolutionize transdermal release of “difficult-to-formulate” compounds targeting the endocannabinoid system.

Tetra Pharm Technologies has focused intensively on formulation expertise, that is, how the molecules are effectively integrated with a drug delivery system to reach their desired targets. Glysious has worked rigorously on the development of an adhesive patch for transdermal drug delivery since the company’s incorporation in 2020.
“The Glysious technology enables precision, sustained dosing, and allows for a high drug load and effective emptying of patches. The transdermal patches remain in place and are very comfortable and convenient to use, resulting in improved patient compliance. However, we have identified challenges with standard formulation strategies, not providing acceptable drug release due to shortcomings of the formulation matrix”, says Professor, Dr.Techn. Anne Ladegaard Skov, Chief Scientific Officer, Glysious.
Back in 2023 Glysious and Tetra Pharm Technologies performed early in-vitro feasibility tests, integrating Tetra Pharma Technologies’ proprietary enabling technology for delivery of poorly soluble compounds with Glysious’ patch.
Dr. Morten Allesø, Chief Scientific Officer, Tetra Pharm Technologies, adds: “Although both parties were aware of the uniqueness of our respective technologies, we were positively surprised to find a five-fold increase in performance of our combination product compared to conventional formulation technologies. This is truly remarkable, and we consider it our shared obligation to further advance this technology to the benefit of the patients.”
The objectives of the collaboration include conducting comprehensive in-vitro and in-vivo studies to evaluate the performance and efficacy of the combined drug delivery system. Additionally, Tetra Pharm Technologies and Glysious plan to pursue a common patent for the joint invention, ensuring that their innovative technology remains protected and exclusive.
“We are excited to collaborate with the innovative team in Tetra Pharm Technologies on this transdermal drug delivery system paving the way for commercialization and scaling of the Glysious technology within the pharma segment”, says Stina Bjerg Nielsen, Chief Executive Officer, Glysious.
Martin Rose, Chief Executive Officer, Tetra Pharm Technologies, concludes: “The collaboration represents a unique opportunity to harness the synergies between our respective technologies. By combining our expertise, we aim to develop a transdermal drug delivery system that offers superior efficacy, convenience, and patient compliance, supporting several of our pipeline programs”.
As part of the collaboration, the partners will exchange expertise, knowledge, and resources. In addition, Tetra Pharm Technologies and Glysious will conduct joint research, experiments, and tests as required for the development of a joint patent. The scope of the collaboration is focused on disease indications such as pain, sleep disorders, and appetite regulation.
About Tetra Pharm Technologies
Tetra Pharm Technologies is a Danish biopharmaceutical company established in 2018 with a vision to be a leader in research and development of pharmaceutical drugs for the treatment of diseases related to the endocannabinoid system. For more information, please visit www.tetrapharm.eu
About Glysious
Glysious is a Danish medtech company, incorporated in 2020, that develops patches, creams, spray, and foams with controlled release of active ingredients for cosmetics and life science applications. For more information, please visit www.glysious.com
For further informationJacob SchlundtChief Marketing OfficerTetra Pharm [email protected]+45 51976225
Stina Bjerg NielsenChief Executive [email protected]+45 3053 5393
Photo – https://mma.prnewswire.com/media/2393210/Tetra_Pharm_Technologies_Deal.jpgLogo – https://mma.prnewswire.com/media/1988863/Tetra_Pharm_Technologies_Logo.jpg
 
 
 

View original content:https://www.prnewswire.co.uk/news-releases/tetra-pharm-technologies-and-glysious-announce-collaboration-to-develop-transdermal-combination-drugs-targeting-the-endocannabinoid-system-302123136.html

Continue Reading

Trending